August 24, 2022 (HORSHAM, PA)– The Janssen Pharmaceutical Companies ofJohnson & Johnsonannounced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA®(ibrutinib) for the treatment of pediatric patients one...
Imbruvica (ibrutinib) FDA Approval History More news resources Subscribe to our newsletter Whatever your topic of interest,subscribe to our newslettersto get the best of Drugs.com in your inbox. Drug Status AvailabilityPrescription onlyRx Pregnancy & LactationRisk data avai...
Medical Disclaimer Drug Status AvailabilityPrescription onlyRx Pregnancy & LactationRisk data available CSA Schedule* Not a controlled drug N/A Approval History Drug history at FDA
FDA approval: ibrutinib for patients with previously treated Mantle cell lymphoma and previously treated chronic lymphocytic leukemia Clin Cancer Res, 21 (16) (2015 Aug 15), pp. 3586-3590, 10.1158/1078-0432.CCR-14-2225 PMID: 26275952 View in ScopusGoogle Scholar [13] W.G. Wierda, J. Brown...
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.What to Read Next on Medscape News & Perspective JNJ, AbbVie Plan to Pull US Accelerated Approvals for Some Blood Cancer...
In February 2014, the FDA approved ibrutinib for patients with previously treated CLL, which was then followed by a full FDA approval and a new indication for high-risk patients with 17p deletions in July 2014. Ibrutinib was also granted an indication for ibrutinib Waldenström’s ...
Research shows a high occurrence of ibrutinib-related cardiotoxicity in patients with cancer. This is the first study showing such evidence.
November 29th 2024 FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL February 2nd 2025 Five Under 5: Top Oncology Videos for the Week of 1/26 March 19th 2024 Revisit the OncLive On Air Episodes From February 2024 January 31st 2025 MB-105 Receives Orphan Drug Designation in Relapsed...
Medical Disclaimer Drug Status AvailabilityPrescription onlyRx Pregnancy & LactationRisk data available CSA Schedule* Not a controlled drug N/A Approval History Drug history at FDA
Acalabrutinib Plus Bendamustine and Rituximab Receives FDA Approval in MCL Sabrina Serani;Jordyn Sava January 17th 2025 Article Acalabrutinib with bendamustine and rituximab is now an FDA-approved treatment for patients with previously untreated mantle cell lymphoma. Read More...